- For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it.
- However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients.
- Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System.
Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm to surrounding healthy tissue. While it has been around for decades, it’s been largely inaccessible for many cancer patients due to both the huge footprint of traditional proton therapy equipment and the high costs. However, some programs have recently turned their heads to proton therapy and are attempting to make it more accessible for those who can benefit from it.
For example, Stanford School of Medicine recently opened a new facility that offers proton therapy that’s more accessible than in the past. Working alongside medical tech companies, the university was able to shrink down the size and cost of the proton therapy equipment, making it easier for more people to access.
In addition to Stanford, companies such as Liora Technologies are also looking to make proton therapy a more accessible and viable treatment option for the patient population. Liora Technologies, a UK-based subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), that is pioneering the electronically controlled therapy that represents a shift in proton delivery.
The system, called the Linac for Image Guided Hadron Therapy (“LiGHT”) system, is a compact and modular platform that uses an electronically-controlled beam to minimize proton loss and speed up energy switching, to provide a more efficient treatment. The LiGHT system is also smaller in size, more affordable, and quicker to deploy than traditional proton therapy systems.
The system also complements LIXTE’s lead clinical candidate, called LB-100. LB-100 is a protein phosphatase 2A (“PP2A”) inhibitor that is designed to enhance the effectiveness of treatments like chemotherapy and immunotherapy by preventing the cancer cells from repairing themselves from the damage caused by these therapies.
Together, the pair combine to make a more effective treatment as the LB-100 makes cancer cells more vulnerable to radiation, and the LiGHT system delivers high-precision radiation only where it needs to go.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing differentiated cancer therapies. Instead of introducing standalone treatments, the company focuses on a first-in-class approach that aims to enhance the effectiveness of established cancer therapies. Specifically, LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with unmet medical need.
For more information, visit the company website at https://lixte.com
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT
